Gannet BioChem Filing Paves Way for More Affordable Cancer Drugs

HUNTSVILLE, AL – March 10, 2026 – Gannet BioChem, a specialized Alabama-based life sciences manufacturer, has taken a significant step that could accelerate the availability of more affordable cancer supportive care drugs in the United States. The company announced today it has filed a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration for its mPEG propionaldehyde 20K, a critical component used in making pegfilgrastim biosimilars.

This regulatory maneuver, while technical, has significant real-world implications. It is designed to streamline the development and approval process for pharmaceutical companies creating biosimilar versions of pegfilgrastim, a vital medication used to reduce the risk of infection in patients undergoing chemotherapy. By making it easier for drug developers to source a key, high-quality ingredient from a compliant, U.S.-based facility, the move could intensify market competition and ultimately lower healthcare costs.

The Ripple Effect on Cancer Care and Costs

For thousands of cancer patients, chemotherapy brings with it the perilous risk of neutropenia—a dangerous drop in white blood cells that leaves the body vulnerable to infection. Pegfilgrastim, sold for years under the brand name Neulasta, is a biologic drug that stimulates the growth of these cells, serving as a crucial line of defense. However, the high cost of originator biologics has long been a burden on patients and the healthcare system.

The emergence of biosimilars—highly similar, lower-cost versions of original biologic drugs—has been a game-changer. The global pegfilgrastim biosimilar market, valued at over $1.6 billion in 2024, is projected to surge to nearly $2.6 billion by 2033. This growth is fueled by the significant cost savings they introduce. Market data shows that biosimilars can drive the average sales price down by over 50% within five years of launching, creating a more competitive landscape that benefits payers and patients alike.

Gannet BioChem’s regulatory filing is poised to add momentum to this trend. By providing a pre-vetted, reliable source for mPEG propionaldehyde 20K—the activated polymer that gives pegfilgrastim its long-acting properties through a process called PEGylation—the company is effectively lowering a key barrier to entry for other drug makers. A more accessible supply of this critical component can empower more companies to develop and launch their own pegfilgrastim biosimilars, increasing supply and driving prices down further.

A Regulatory Fast Pass for Drug Developers

At its core, Gannet BioChem’s filing of a Type II Drug Master File is a strategic move to enhance efficiency for its customers. A DMF is a confidential submission to the FDA containing detailed information about the facilities, processes, and materials used in manufacturing a drug component. Instead of each drug developer having to independently provide and validate this information for the component they are sourcing, they can simply reference Gannet BioChem's DMF in their own Biologics License Application.

This “by-reference” system offers two major advantages. First, it protects the proprietary intellectual property of the component manufacturer while giving the FDA full transparency for its review. Second, and more importantly for the market, it significantly shortens review cycles and reduces the regulatory burden on biosimilar developers. This can accelerate the overall time-to-market, a critical factor in the highly competitive pharmaceutical industry.

The filing from the company's Arab, Alabama facility also serves as a stamp of quality and compliance, assuring potential partners that the component is manufactured under the FDA's rigorous standards. This assurance is vital for any company building a complex biologic drug where the quality of every raw material is paramount.

Fortifying the U.S. Biopharmaceutical Supply Chain

The announcement also resonates with a powerful theme in post-pandemic America: strengthening the domestic pharmaceutical supply chain. The COVID-19 pandemic exposed critical vulnerabilities stemming from a heavy reliance on foreign countries, particularly China and India, for active pharmaceutical ingredients (APIs) and other essential drug components. In response, shoring up domestic manufacturing has become a bipartisan national priority.

Gannet BioChem, with its FDA-inspected manufacturing facilities in Huntsville and Arab, Alabama, is positioning itself as a key part of the solution. By offering a U.S.-made, compliant source for a critical biopharmaceutical component, the company helps mitigate supply chain risks for drug developers and contributes to national biopharmaceutical security.

This strategic importance was underscored by Nicholas Shackley, the company’s Chief Executive Officer. “This filing supports a fully compliant, US-based supply of critical components that enable the development of more affordable medicines, addressing infection risks for patients undergoing chemotherapy,” he stated in the company's announcement.

The Strategy Behind the Science

This regulatory milestone is not an isolated event but the latest step in a deliberate growth strategy. The filing follows Gannet BioChem's acquisition of Laysan Bio earlier this year, a move that significantly expanded its manufacturing capacity, product portfolio, and technical expertise. The integration combined Gannet BioChem's large-scale cGMP manufacturing capabilities with Laysan Bio's strength in custom polymer development, creating an end-to-end partner for drug developers from gram-scale research to commercial supply.

The company's expertise is highly specialized. PEGylation, the process of attaching polyethylene glycol (PEG) polymers to a therapeutic protein, is a widely used technique to improve a drug's solubility, stability, and pharmacokinetic profile, allowing it to remain in the body longer and work more effectively. Gannet BioChem’s deep bench of scientific talent and its track record—having supported nine commercial PEGylated therapies and over 50 development programs—make it a leading player in this niche but essential field.

As the company prepares to meet with industry partners at the upcoming DCAT Week in New York, the message is clear. With a strengthened U.S. manufacturing base, a streamlined regulatory pathway for its partners, and a clear strategic vision, Gannet BioChem is positioning itself not just as a supplier, but as a foundational pillar in the future of biopharmaceutical development.